Serdal Ugurlu

Trakya University, Adrianoupolis, Edirne, Turkey

Are you Serdal Ugurlu?

Claim your profile

Publications (49)144.63 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Impaired physical performance is a disturbing complication of acromegaly. We aimed to evaluate the role of regular exercise in amelioration of the impaired physical performance in acromegaly. Patients with acromegaly were divided into two groups according to their participation in a prescheduled program of exercise. Participants in the study group exercised 3 days a week for 3 consecutive months. Exercise tolerance was evaluated by maximal oxygen consumption (VO2 max) and time (T) taken to complete the Bruce protocol, muscle flexibility by the sit and reach test (SRT) and muscle strength by the hand grip strength test (HGST). Concomitantly, anthropometric assessment was done using body mass index (BMI), waist to hip ratio (WHR), skinfold measurements from 8 points, percentage body fat (PBF), fat mass (FM) and lean body mass (LBM). After 3 months of exercise VO2 max and T were higher in cases that exercised than in cases that did not (p=0.004 and p=0.001). Over 3 months, within the exercise group, VO2 max and T of the Bruce protocol increased (p=0.003 and p=0.004) and heart rate during warming decreased (p=0.04). SRT increased within the exercise group after 3 months (p=0.004). HGSRT did not change significantly (right p=0.06 and left p=0.2). The sum of skinfolds, BMI, WHR and LBM remained stable over the study period (p=0.1, p=0.08, p=0.3 and p=0.09). PBF decreased slightly and FM decreased significantly over 3 months (p=0.05 and p=0.03). Even short-term exercise may improve impaired physical performance, muscle activity and disturbed body fat composition in acromegaly. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Clinical Endocrinology 12/2014; · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Behçet's syndrome (BS) is a well-recognized cause of Budd-Chiari syndrome (BCS); however, information about its clinical characteristics and outcome is limited. METHODS: We reviewed the records of about 9000 patients with BS registered at the multidisciplinary Behçet's syndrome outpatient clinic at Cerrahpasa Medical Faculty between July 1977 and October 2013. We identified 43 (40 M/3 F) patients who were diagnosed as having BCS. Their outcome was evaluated between September 2012 and October 2013. RESULTS: In total, 33 patients (77%) had presented with liver-related symptoms (Group I), while 10 (23%) were asymptomatic for liver disease (Group II). This latter group had presented with symptoms related to the presence of major vessel disease such as fever, leg swelling, or dyspnea. The site of venous obstruction determined in 41 patients was inferior vena cava (IVC) and hepatic veins combined in 25 (61%), IVC alone in 12 (29%), and only hepatic veins in 4 patients (10%). The number of patients with concurrent obstruction in the hepatic veins and the IVC was less in Group II than in Group I (3/10 vs 22/31, p = 0.06). A total of 20 (19 M/1 F) patients (47%) had died at a median of 10 months after diagnosis. Mortality was significantly lower in Group II (10%) than in Group I (58%), (p = 0.011). By the end of the survey, 23 patients were alive, of whom 21 could be re-evaluated at the clinic. CONCLUSIONS: BCS associated with BS is usually due to IVC thrombosis with or without hepatic vein thrombosis. Silent cases exist and have a better prognosis. The mortality rate among the patients symptomatic for liver disease remains high.
    Seminars in Arthritis and Rheumatism 12/2014; · 3.63 Impact Factor
  • Clinical and experimental rheumatology 09/2014; 32 Suppl 84(4):175. · 2.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Some features of Behçet's syndrome (BS) tend to go together. We aimed to explore the association and timing of various vascular events in both the venous and the arterial vascular tree.
    Rheumatology (Oxford, England) 06/2014; · 4.44 Impact Factor
  • Caner Saygin, Didem Uzunaslan, Serdal Ugurlu
    Laboratory hematology: official publication of the International Society for Laboratory Hematology 06/2014; 20(2):7-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The introduction of TNF inhibitors into clinical practice has revolutionalised the treatment of most inflammatory diseases. However, these drugs are associated with various and potentially serious side effects. Despite being rare, demyelinating neuroinflammatory disordes including multiple sclerosis, optic neuritis, transverse myelitis, polyradiculoneuropathy, and Guillain-Barre Syndrome (GBS) have been reported after using anti-TNF drugs, particularly with infliximab. Adalimumab is a newer fully humanised monoclonal anti-TNF antibody and to date, transverse myelitis during the course of adalimumab treatment has never been reported. Herein, we describe a patient who received adalimumab for management of his ankylosing spondylitis (AS) and developed synchronous transverse myelitis and GBS after therapy. A 69-year old male with a 30-year history of AS, was admitted to neurology clinic with lower extremity weakness. Physical examination revealed bilateral 5/5 and 0/5 motor strengths in upper and lower extremities, respectively. He did not have sphincteric or sensorial deficits, cerebellar symptoms, or aphasia. He had received adalimumab treatment for 8 months (40 mg subcutaneously every 2 weeks) which controlled his refractory AS symptoms, but the patient had stopped taking the drug 3 months before the onset of his symptoms. MRI showed increased signal intensity at distal spinal cord which supported the diagnosis of myelitis. After one week course of pulse steroids, the patient responded well and gained full strength. One month later, he presented again with bilateral lower extremity weakness and falls, and physical examination showed full strength in upper extremity and muscle strength was 2/5 on right and 0/5 on left lower extremity. He had hypotonia and hyporeflexia on the right and areflexia on the left lower extremity. Repeated MRI scan showed regressed spinal lesion, lumbar puncture revealed elevated protein levels (107 mg/dL) and EMG was compatible with GBS. The patient received intravenous immunoglobulin and showed gradual improvement in lower extremity muscle strength. Central and peripheral progressive demyelinating neuroinflammatory lesions might occur during anti-TNF treatment, with the latter being more common than central nervous system involvement. There are a few reports indicating an association between adalimumab and GBS in patients with rheumatoid arthritis, but synchronous occurence of transverse myelitis and GBS is so unusual, and both diseases responded well to standard measures.
    Annals of the rheumatic diseases 03/2014; 73 Suppl 1:A40-1. · 9.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To test the hypothesis that colchicine use during early disease decreases immunosuppressive use in Behçet syndrome (BS) in the long term. Patients with BS who participated in a double-blind, placebo-controlled trial of colchicine 16.6 ± 1.1 years ago were evaluated for immunosuppressive use during the posttrial period. We could contact 90/116 patients; 28 (31%) received immunosuppressives during the posttrial period, 14 being from the colchicine arm. Posttrial colchicine use and cumulative duration were similar between patients who received immunosuppressives and those who did not. Continuous use of colchicine, even when initiated at an early disease stage, does not seem to decrease the use of immunosuppressives in the long term.
    The Journal of Rheumatology 02/2014; 41(4). · 3.17 Impact Factor
  • Annals of the Rheumatic Diseases 01/2014; 72(Suppl 3):A641-A642. · 9.27 Impact Factor
  • Annals of the Rheumatic Diseases 01/2014; 71(Suppl 3):707-707. · 9.27 Impact Factor
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-wide association studies (GWAS) are a powerful means of identifying genes with disease-associated common variants, but they are not well-suited to detecting genes with disease-associated rare and low-frequency variants. In the current study of Behçet disease (BD), nonsynonymous variants (NSVs) identified by deep exonic resequencing of 10 genes found by GWAS (IL10, IL23R, CCR1, STAT4, KLRK1, KLRC1, KLRC2, KLRC3, KLRC4, and ERAP1) and 11 genes selected for their role in innate immunity (IL1B, IL1R1, IL1RN, NLRP3, MEFV, TNFRSF1A, PSTPIP1, CASP1, PYCARD, NOD2, and TLR4) were evaluated for BD association. A differential distribution of the rare and low-frequency NSVs of a gene in 2,461 BD cases compared with 2,458 controls indicated their collective association with disease. By stringent criteria requiring at least a single burden test with study-wide significance and a corroborating test with at least nominal significance, rare and low-frequency NSVs in one GWAS-identified gene, IL23R (P = 6.9 × 10(-5)), and one gene involved in innate immunity, TLR4 (P = 8.0 × 10(-4)), were associated with BD. In addition, damaging or rare damaging NOD2 variants were nominally significant across all three burden tests applied (P = 0.0063-0.045). Furthermore, carriage of the familial Mediterranean fever gene (MEFV) mutation Met694Val, which is known to cause recessively inherited familial Mediterranean fever, conferred BD risk in the Turkish population (OR, 2.65; P = 1.8 × 10(-12)). The disease-associated NSVs in MEFV and TLR4 implicate innate immune and bacterial sensing mechanisms in BD pathogenesis.
    Proceedings of the National Academy of Sciences 04/2013; · 9.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: Atherosclerosis is well recognized in Takayasu arteritis (TAK) and the associated plaques tend to be more common in areas of arteritis. We now report arterial wall calcification in a large group of TAK patients and controls. We hypothesized that the degree of coronary artery calcification would point to a systemic effect of inflammation while that in the thoracic aorta more of local inflammation. METHODS: A total of 47 patients with TAK, 43 patients with SLE and 70 healthy controls (HC) were studied. The presence of coronary artery and thoracic aorta calcifications (ToAC) was investigated by multi-detector computed tomography (MDCT). Atherosclerotic plaques in the carotid arteries were screened using B mode ultrasound. RESULTS: The frequency of coronary artery calcification was significantly increased among patients with SLE as compared to the healthy controls while the increase in TAK did not reach statistical significance. There were more TAK patients with ToAC among the TAK as compared to the SLE patients [21/47 (45%) vs 10/43 (23%), P = 0.033]. In addition, a circumferential type of calcification, vs a punctuate or linear type, was the more common type in 67% of patients with TAK whereas only the linear or punctuate type was seen in SLE patients and HC. SLE and TAK patients were found to have increased risk for carotid artery plaques. Among TAK patients, coronary artery calcification, ToAC and carotid artery plaques tend to be at sites of primary vasculitic involvement. CONCLUSIONS: There is increased atherosclerosis in TAK and SLE. Vessel wall inflammation seems to be also important in the atherosclerosis associated with TAK.
    Seminars in arthritis and rheumatism 01/2013; · 4.72 Impact Factor
  • Pediatric Rheumatology 01/2013; 11(Suppl 1):A19. · 1.62 Impact Factor
  • Pediatric Rheumatology 01/2013; 11(Suppl 1):A269. · 1.62 Impact Factor
  • EULAR 2013; 01/2013
  • Pediatric Rheumatology 01/2013; 11(Suppl 1):A65. · 1.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: The numbers and recurrence rates of mucocutaneous manifestations can be highly variable among patients with Behçet's syndrome (BS) but it is not known whether these differences influence the disease course at the long-term. METHODS: We evaluated the outcome of 30 patients that made up the placebo arm of a 6 months controlled trial of thalidomide and looked at the relation between the frequencies of mucocutaneous manifestations during the trial and the development of major organ involvement necessitating immunosuppressives during the post-trial period. RESULTS: Fifteen (50%) patients had received immunosuppresives for major organ involvement during the post-trial period. Patients receiving immunosuppressive treatment were significantly younger at the onset of BS compared to those who did not (24.5±5 vs. 29.7±3.8 SD years; p=0.003). The mean number of oral ulcers recorded throughout the trial was significantly higher among patients using immunosuppressives compared to those who did not (2.09±0.96 vs. 1.43±0.8; p=0.029). This significance disappeared when adjusted for age of onset of BS (p=0.16). ROC curve analysis showed that having 10 or more ulcers during 6 months has a sensitivity of 86.7% and a specificity of 53% for the subsequent necessity of immunosuppressive use. The same association was not true for genital ulcers, follicular lesions and erythema nodosum. CONCLUSIONS: These findings on a limited number of patients suggest that frequent occurrence of oral ulceration during the initial years of the disease may predict the development of major organ involvement in men with BS.
    Clinical and experimental rheumatology 08/2012; · 2.97 Impact Factor
  • H Yazici, S Ugurlu, E Seyahi
    [Show abstract] [Hide abstract]
    ABSTRACT: Behçet's syndrome (BS) is a disease of unknown etiology, and as such, there have been efforts to classify BS within the popular nosological identities of the times such as seronegative spondarthritides, autoimmune, and more recently autoinflammatory diseases. Current evidence suggests that BS does not easily fit into any one of these lumps, while on occasion, it might be impossible to tell BS from Crohn's disease, especially when the main clinical presentation is intestinal ulceration. There are distinct regional differences in disease expression of BS with fewer cases of intestinal disease in the Mediterranean basin and less severe eye disease and less frequent skin pathergy among patients reported from northern Europe or America. The clustering of symptoms, especially with the recently described increased frequency of the acne/arthritis cluster in familial cases, suggests that more than one pathological pathway is involved in what we call BS today. Supportive evidence for this contention also comes from the observations that (a) the genetic component is very complex with perhaps different genetic modes of inheritance in the adult and in the pediatric patients; and (b) there are differing organ responses to one same drug. For example, the anti-TNF agents successfully control the oral ulcers while they have no effect on the pathergy reaction.
    Clinical Reviews in Allergy & Immunology 06/2012; · 4.73 Impact Factor
  • Annals of the rheumatic diseases 05/2012; 71(9):1589-91. · 9.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Aim of this study was to investigate the changes in body composition and some biochemical parameters of women at different age and body mass index (BMI) groups and to evaluate their relations with to cardiometabolic risk factors. Methods: The study was created by retrospective research of the file records of total 800 women who got into nutritional counseling between 2002 -2007 years at Cerrahpasa Medical Faculty. Participants were grouped as 10 -19, 20 -29, 30 -39, 40 -49, 50 -59, ≥60 years according to ages and were divided into 4 groups as nor-mal, overweight, obese and morbidly obese according to body mass index. Data were sta-tistically analysed in SPSS for Windows com-puter program with ANOVA and Tukey HSD tests. Findings: There are significant differences be-tween different age groups in weight, BMI, waist and hip circumferences, percentage of body water, fat and fat-free mass, basal metabolic rate and blood glucose, insulin, triglyceride, choles-terol, HDL, LDL levels and HOMA-IR values. HOMA-IR values were the highest at age group 1 and the lowest at age group 2. Although they were in the same BMI group; their waist cir-cumference, basal metabolic rate and percent of body fat showed significant increases with advancing age. Conclusion: The findings of our study show that it will be useful to use standard values generated for each age group according to BMI levels in predicting increased cardiovas-cular and metabolic risks together with ad-vancing age. While the lowest rate of obesity according to body fat percent (>30%) was found at the ages in between 20 -29 (58.4%), it is noteworthy that the obesity rate with respect to their body fat percent has been noticed at the ages of 10 to 19 (2.3%). Comparing with the other groups, significantly higher body heights found at the ages in between 10 -19, could pos-sibly predicate that the new generations are hav-ing better nutrition and overhaul. On the other hand, it was known that as a result of eating bugs and/or over-nutrition, besides insertion of inactive life style, children have become more sensitive to obesity and related health problems. As seen in our study, the healthiest values are at the ages in between 20 -29, the results were commentated as the women at those ages are showing more interest in their physical appea-rance and their health. In accordance with our study's data, in order to cope with obesity and related illnesses, which are having an impor-tance in public health, we concluded that gene-ralizing continuous and effective trainings on nutrition concerning families even the educators starting from the childhood, can be usefull.
    International Journal of Diabetes Mellitus 01/2012; 2:12-18.

Publication Stats

268 Citations
144.63 Total Impact Points


  • 2014
    • Trakya University
      Adrianoupolis, Edirne, Turkey
  • 2006–2014
    • Istanbul University
      • Department of Family Medicine (Cerrahpasa Faculty of Medicine)
      İstanbul, Istanbul, Turkey
  • 2009–2010
    • Fatih Sultan Mehmet Training and Research Hospital
      İstanbul, Istanbul, Turkey
  • 2008–2009
    • Cumhuriyet University
      • Faculty of Medicine
      Sivas, Sivas, Turkey